Processa Pharmaceuticals, Inc. Income Statement
PCSA|6 years of annual SEC 10-K data (FY2013-FY2022)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 6 fiscal years. All figures from audited SEC 10-K filings.
Processa Pharmaceuticals, Inc. reported $0 in revenue and $11M in net loss for FY2022. Revenue has declined at a 16.1% compound annual rate over the past 3 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -4.39 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2022 | FY2021 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $113.4K | $107.2K | $312.5K | $192.1K |
| Cost of Revenue | - | - | $125.9K | $66.8K | $188.0K | $133.3K |
| Gross Profit | - | - | -$12.5K | $40.4K | $124.5K | $58.9K |
| SG&A Expense | $4.7M | $3.3M | $945.5K | $2.0M | $2.8M | $1.9M |
| R&D Expense | $6.9M | $3.2M | $29.2K | $178.1K | $267.1K | $448.0K |
| Operating Income | -$12.1M | -$15.1M | - | - | - | - |
| Interest Expense | - | $281.1K | $235.6K | $315.3K | -$109.7K | -$170.7K |
| Income Tax | -$530.6K | -$1.0M | -$100 | -$100 | -$50 | -$181 |
| Net Income | -$11.4M | -$14.4M | -$3.4M | -$4.5M | -$3.1M | -$2.4M |
| EPS (Basic) | -$0.75 | - | - | - | - | - |
| EPS (Diluted) | - | -$2.54 | -$0.31 | -$0.68 | -$0.61 | -$1.50 |
| Shares Outstanding | 15.7M | 14.2M | 11.0M | 11.0M | 8.1M | 1.8M |
| Gross Margin | - | - | -11.0% | 37.7% | 39.8% | 30.6% |
| Profit Margin | - | - | -2957.2% | -4220.7% | -982.0% | -1270.1% |